TKL Research, a US-based clinical research organisation (CRO) that focuses on enrolment-driven Phase I-IV clinical trials, has expanded its presence and capabilities in Europe by taking an equity position in Germany-based CRO Proinnovera.
Proinnovera offers a full range of clinical research services for Phase I-IV clinical trials throughout Europe. Proinnovera offers expertise in several therapeutic areas including dermatology, pain management, allergy/respiratory, oncology, and vaccines.
Proinnovera's clinical trial services include monitoring, medical affairs, project management, regulatory, and consulting services for pharmaceutical, biotech, and medical device development programs.
Jon Anderson, president and CEO of TKL Research, said: "This partnership will significantly increase TKL's capacity to provide services to more US-based sponsors looking for clinical trial services in Europe. We will be better established in Europe, have a solid understanding of European sites, offer a dynamic network of medical specialists and hospitals, and, as with our US operations, apply this expertise to accelerate patient enrolment."
Robert Reardon, executive vice president and COO of TKL, said: "Having a base in the US and in Europe will facilitate providing services to our clients for Phase I-IV studies. Our reputation for reducing clinical trial timelines by taking responsibility for enrolment and site selection was an important element in our decision to move forward with Proinnovera.
"Both of our organisations excel at enrolment-driven trials. Both are committed to quality Phase I-IV clinical research, work closely with sponsors to help evaluate sites' capabilities, and deliver subjects ahead of schedule. This similar approach to clinical trials will provide our clients with seamless study management and expanded capabilities."